SCHEMBL1526084

SCHEMBL1526084

CCOC(=O)c1cc(-c2cc(F)cc(Cl)c2)n(-c2ccc(F)c(Cl)c2)n1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.54
CA9 Q16790 3/20 0.48
FAAH O00519 2/20 0.47
RXFP1 Q9HBX9 1/20 0.45
MGLL Q99685 1/20 0.45
RPA1 P27694 4/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
TP53 P04637 1/20 0.42
RXRA P19793 1/20 0.42
RXRB P28702 1/20 0.42
RXRG P48443 1/20 0.42
PPP1CA P62136 1/20 0.42
NOTUM Q6P988 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764884 0.93 CHRNA7 (0.53) CHRNA7CA9FAAHRXFP1MGLL
SCHEMBL1765484 0.91 CHRNA7 (0.52) CHRNA7CA9FAAHRXFP1MGLL
SCHEMBL1764893 0.90 CHRNA7 (0.51) CHRNA7CA9FAAHRXFP1MGLL
SCHEMBL1765031 0.89 CHRNA7 (0.60) CHRNA7CA9FAAHRXFP1MGLL
SCHEMBL1765050 0.89 CHRNA7 (0.50) CHRNA7CA9FAAHRXFP1MGLL
SCHEMBL1764980 0.89 CHRNA7 (0.53) CHRNA7CA9FAAHRXFP1MGLL
SCHEMBL1764878 0.89 TP53 (0.53) CHRNA7CA9FAAHMGLLGABRA2
SCHEMBL1765054 0.89 CHRNA7 (0.49) CHRNA7CA9FAAHRXFP1MGLL
SCHEMBL1765056 0.88 CHRNA7 (0.50) CHRNA7CA9FAAHMGLLRPA1
SCHEMBL12838856 0.85 RPA1 (0.50) RPA1MEN1KMT2AATMRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295038-B1 Solid dispersion comprising an anti-HIV agent AICURIS GMBH & CO KG (DE) 2013-05-29 EP disclosed
EP-2295038-B1 Solid dispersion comprising an anti-HIV agent AICURIS GMBH & CO KG (DE) 2013-05-29 EP disclosed
US-20130072531-A1 SOLID DISPERSION COMPRISING AN ANTI-HIV AGENT AICURIS GMBH & CO. KG (DE) 2013-03-21 US disclosed
US-20130072531-A1 SOLID DISPERSION COMPRISING AN ANTI-HIV AGENT AICURIS GMBH & CO. KG (DE) 2013-03-21 US disclosed
US-20130072531-A1 SOLID DISPERSION COMPRISING AN ANTI-HIV AGENT AICURIS GMBH & CO. KG (DE) 2013-03-21 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
WO-2011029909-A1 SOLID DISPERSION COMPRISING AN ANTI-HIV AGENT AICURIS GMBH & CO. KG (DE) 2011-03-17 WO disclosed
WO-2011029909-A1 SOLID DISPERSION COMPRISING AN ANTI-HIV AGENT AICURIS GMBH & CO. KG (DE) 2011-03-17 WO disclosed
EP-2295038-A1 Solid dispersion comprising an anti-HIV agent AiCuris GmbH & Co. KG (DE) 2011-03-16 EP disclosed
EP-2295038-A1 Solid dispersion comprising an anti-HIV agent AiCuris GmbH & Co. KG (DE) 2011-03-16 EP disclosed
WO-2011012630-A1 SUBSTITUTED BIS-ARYL PYRAZOLE AMIDES HAVING TERMINAL PRIMARY AMIDE FUNCTIONALIZATION FOR TREATING RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2011-02-03 WO disclosed
WO-2009115213-A1 (PYRAZOLYL CARBONYL)IMIDAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF RETROVIRAL DISEASES AICURIS GMBH & CO. KG (DE) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO CHRNA7 3365/4885CA9 4825/4885FAAH 4725/4885
US-20130072531-A1 SOLID DISPERSION COMPRISING AN ANTI-HIV AGENT SORD, SUDS3, SUPT16H CHRNA7 4560/4885CA9 3870/4885FAAH 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.